Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
In 2022, 44% of SHA-PUPs and 25% of SHA-PTPs received emicizumab prophylaxis. Concomitantly, observed inhibitor incidence reduced to 6% in SHA-PUPs. In SHB, EHL-rFIX treatment increased to 79% in SHB-PUPs and 69% in SHB-PTPs. Assessing inhibitor incidence for new concentrates is likely to be hampered by novel treatments causing delayed exposure to FVIII/FIX.
Authors
- Kathelijn Fischer (ORCID: https://orcid.org/0000-0001-7126-6613)
- Michael Makris (ORCID: https://orcid.org/0000-0001-7622-7939)
- Samantha C. Gouw (ORCID: https://orcid.org/0000-0002-1957-4122)
- Rob Hollingsworth
- Radosław Kaczmarek (ORCID: https://orcid.org/0000-0001-8084-1958)
- Riitta Lassila (ORCID: https://orcid.org/0000-0002-1911-3094)
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Thierry Lambert (ORCID: https://orcid.org/0000-0001-6391-5839)
- Diana Carbonero
- Alex Gatt
Institutions
- University of Helsinki (FI)
- University of Milan (IT)
- Utrecht University (NL)
- Université Paris-Saclay (FR)
- Helsinki University Hospital (FI)
- Mater Dei Hospital (MT)
- Canadian Hemophilia Society (CA)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University Medical Center Utrecht (NL)
- Emma Kinderziekenhuis (NL)
- Assistance Publique – Hôpitaux de Paris (FR)
- Amsterdam University Medical Centers (NL)
- Bicêtre Hospital (FR)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- University of Amsterdam (NL)
- University of Sheffield (GB)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1111/hae.70039
- Citations
- 6
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 10.62
Funders
- Pfizer
- Bayer
- Roche
- Sanofi
- Biogen
- CSL Behring
- Baxalta
- Octapharma
- European Commission
- European Association for Haemophilia and Allied Disorders
- Swedish Orphan Biovitrum
- Grifols
- Executive Agency for Health and Consumers